[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655540":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":20,"studyPopulation":21,"armGroups":16,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":62,"collaborators":65,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":16,"enrollmentInfo":76,"targetDuration":16,"studyType":79,"phases":16,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":41,"whyStopped":16,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Thromboembolic events","Any newly developed thrombotic event (or acute worsening of a previous one) occurring within: Pulmonary embolism, stroke, venous trombosis","3 months post-surgery",{"measure":10,"description":14,"timeFrame":15},"Any thromboembolic events","first postoperative month",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":19,"maskingInfo":16},"COHORT","PROSPECTIVE","The main hypothesis is Adult patients with glial tumors who present a pattern of hypercoagulability in laboratory parameters and\u002For thromboelastometry have a higher incidence of thromboembolic events and lower survival compared with patients without a hypercoagulability pattern.","Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent",[23],{"type":24,"name":25,"description":26,"armGroupLabels":16,"otherNames":16},"DIAGNOSTIC_TEST","Thromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -","* Molecular markers: including Next-Generation Sequencing (Oncomine Comprehensive Assay v3 or Oncomine Precision Assay) when available.\n* MGMT promoter methylation status.",[28],{"name":29,"affiliation":30,"role":31},"Paola Hurtado Restrepo, MD, PhD","Hospital Clinic of Barcelona","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":16,"email":37},"Paola A Hurtado, MD, PhD","CONTACT","34 932275558","phurtado@clinic.cat",[39],{"facility":40,"status":41,"city":42,"state":16,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hospital Clínic Barcelona","RECRUITING","Barcelona","08036","Spain","ES",{"type":47,"coordinates":48},"Point",[49,50],2.15899,41.38879,{"lat":50,"lon":49},[53,57,60,61],{"name":54,"role":35,"phone":55,"phoneExt":56,"email":37},"Paola Hurtado, MD, PhD","+34932275558","5558",{"name":58,"role":35,"phone":55,"phoneExt":56,"email":59},"Javier Bellafont, MD","fbellafont@clinic.cat",{"name":54,"role":31,"phone":16,"phoneExt":16,"email":16},{"name":58,"role":31,"phone":16,"phoneExt":16,"email":16},{"type":31,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":30,"oldNameTitle":16,"oldOrganization":16},"Paola Hurtado","MD, PhD",[66],{"name":30,"class":6},"100655540","usefulness-of-thromboelastography-as-a-predictor-of-prognosis-in-patients-undergoing-surgery-for-glial-tumors-and-of-the-risk-of-postoperative-thromboembolic-disease-glitem-100655540",false,"NCT07813377","Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)","GliTEM","Inclusion Criteria:\n\n* Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Emergency surgery.\n* Patients receiving antiplatelet or anticoagulant treatment.\n* Patients with known hematologic diseases associated with coagulation abnormalities. Examples include:\n\n  * Congenital or acquired platelet function disorders.\n  * Congenital deficiency of protein C or protein S.\n  * Deficiency of coagulation factors II, V, VII, X, XII.\n  * Glanzmann thrombasthenia.\n  * Hemophilia A, B, or C.\n  * Idiopathic thrombocytopenic purpura (ITP).\n  * von Willebrand disease (types I, II, and III).\n* Systemic diseases that cause significant coagulation time alterations:\n\n  * Prothrombin time \\\u003C 60%.\n  * Activated partial thromboplastin time (aPTT) \\> 50 seconds.\n* Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy","ALL","18 Years",{"count":77,"type":78},100,"ESTIMATED","OBSERVATIONAL","The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.",[82,83,84],"Glial Tumors","Thrombosis","Pulmonary Embolism (Diagnosis)",[86,83,87],"Glial tumors","thromboelastometry","2026-09-04",{"date":90,"type":91},"2026-09-10","ACTUAL",{"date":93,"type":91},"2026-05-30",{"date":95,"type":78},"2027-05-30",{"name":5,"class":6},1]